

NCT00250640 comparison:

Summary:
CHIA has 4 criteria while your personal folder has 4 criteria
Total found criteria: 4/4
Total not Found: 0/4
Total Extra: 1
This trial is VALID



╒═══════════════════════════════════════════════════╤═══════════════════════════════════════════════════╕
│ CHIA Criteria                                     │ Matching Personal Criteria                        │
╞═══════════════════════════════════════════════════╪═══════════════════════════════════════════════════╡
│ The treating physician has chosen Ventavis as a   │ The treating physician has chosen Ventavis as a   │
│ suitable long-term treatment for the patient      │ suitable long-term treatment for the patient      │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Patient with primary pulmonary hypertension (i.e. │ Patient with primary pulmonary hypertension (i.e. │
│ Idiopathic Pulmonary Arterial Hypertension or     │ Idiopathic Pulmonary Arterial Hypertension or     │
│ Familial Pulmonary Arterial Hypertension) and     │ Familial Pulmonary Arterial Hypertension) and     │
│ classified as NYHA functional class III (NYHA =   │ classified as NYHA functional class III (NYHA =   │
│ New York Heart Association)                       │ New York Heart Association)                       │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ No prior treatment with Ventavis or other active  │ No prior treatment with Ventavis or other active  │
│ treatments for primary pulmonary hypertension     │ treatments for primary pulmonary hypertension     │
│ within 6 weeks of date of study inclusion (unless │ within 6 weeks of date of study inclusion (unless │
│ otherwise advised by Bayer Schering Pharma)       │ otherwise advised by Bayer Schering Pharma)       │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Any condition that prevents participation in the  │ Any condition that prevents participation in the  │
│ study, including pregnancy and other              │ study, including pregnancy and other              │
│ contraindications for Ventavis treatment (as      │ contraindications for Ventavis treatment (as      │
│ listed in the current Ventavis Summary of Product │ listed in the current Ventavis Summary of Product │
│ Characteristics and patient package insert)       │ Characteristics and patient package insert)       │
╘═══════════════════════════════════════════════════╧═══════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛